Editas Medicine (EDIT) Competitors $3.01 +0.01 (+0.33%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$3.00 -0.01 (-0.33%) As of 09:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EDIT vs. BEAM, CRSP, NTLA, ATAI, CRON, TRVI, RAPP, PHAR, UPB, and SPRYShould you be buying Editas Medicine stock or one of its competitors? The main competitors of Editas Medicine include Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), atai Life Sciences (ATAI), Cronos Group (CRON), Trevi Therapeutics (TRVI), Rapport Therapeutics (RAPP), Pharming Group (PHAR), Upstream Bio (UPB), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Editas Medicine vs. Its Competitors Beam Therapeutics CRISPR Therapeutics Intellia Therapeutics atai Life Sciences Cronos Group Trevi Therapeutics Rapport Therapeutics Pharming Group Upstream Bio ARS Pharmaceuticals Beam Therapeutics (NASDAQ:BEAM) and Editas Medicine (NASDAQ:EDIT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership. Do insiders & institutionals hold more shares of BEAM or EDIT? 99.7% of Beam Therapeutics shares are owned by institutional investors. Comparatively, 71.9% of Editas Medicine shares are owned by institutional investors. 3.5% of Beam Therapeutics shares are owned by insiders. Comparatively, 1.9% of Editas Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is BEAM or EDIT more profitable? Editas Medicine has a net margin of -608.88% compared to Beam Therapeutics' net margin of -661.31%. Beam Therapeutics' return on equity of -43.15% beat Editas Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Beam Therapeutics-661.31% -43.15% -31.06% Editas Medicine -608.88%-200.25%-68.57% Which has more volatility and risk, BEAM or EDIT? Beam Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Editas Medicine has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Do analysts recommend BEAM or EDIT? Beam Therapeutics presently has a consensus target price of $46.40, suggesting a potential upside of 95.53%. Editas Medicine has a consensus target price of $5.10, suggesting a potential upside of 69.44%. Given Beam Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than Editas Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 3 Strong Buy rating(s) 3.08Editas Medicine 2 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.23 Which has stronger earnings & valuation, BEAM or EDIT? Editas Medicine has lower revenue, but higher earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBeam Therapeutics$63.52M37.79-$376.74M-$4.50-5.27Editas Medicine$32.31M8.38-$237.09M-$2.85-1.06 Does the media favor BEAM or EDIT? In the previous week, Beam Therapeutics had 5 more articles in the media than Editas Medicine. MarketBeat recorded 5 mentions for Beam Therapeutics and 0 mentions for Editas Medicine. Beam Therapeutics' average media sentiment score of 0.42 beat Editas Medicine's score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Beam Therapeutics Neutral Editas Medicine Neutral SummaryBeam Therapeutics beats Editas Medicine on 12 of the 17 factors compared between the two stocks. Get Editas Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EDIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EDIT vs. The Competition Export to ExcelMetricEditas MedicineMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$269.76M$3.16B$5.76B$10.50BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-1.0621.0476.2526.62Price / Sales8.38252.06470.4991.77Price / CashN/A46.3537.4661.85Price / Book1.859.7813.356.45Net Income-$237.09M-$52.73M$3.29B$271.57M7 Day Performance10.66%3.16%1.83%2.55%1 Month Performance7.50%4.69%3.98%7.22%1 Year Performance-14.73%16.37%74.39%29.60% Editas Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EDITEditas Medicine3.8677 of 5 stars$3.01+0.3%$5.10+69.4%-17.8%$269.76M$32.31M-1.06230High Trading VolumeBEAMBeam Therapeutics2.9781 of 5 stars$22.91+7.7%$46.40+102.5%-4.0%$2.32B$60.27M-5.09510CRSPCRISPR Therapeutics3.237 of 5 stars$61.19+5.8%$71.60+17.0%+30.0%$5.57B$37.31M-11.27460Analyst ForecastNTLAIntellia Therapeutics4.451 of 5 stars$12.27+6.1%$27.11+121.0%-20.4%$1.32B$52.86M-2.62600ATAIatai Life Sciences3.2594 of 5 stars$4.65flat$11.25+141.9%+367.5%$996.68M$310K-6.7480News CoverageAnalyst ForecastGap UpCRONCronos Group2.5274 of 5 stars$2.59+1.6%N/A+22.8%$991.69M$130.28M51.80450TRVITrevi Therapeutics1.9668 of 5 stars$7.96-1.2%$21.75+173.2%+153.9%$969.35MN/A-18.9520RAPPRapport Therapeutics3.0565 of 5 stars$26.19+5.9%$35.33+34.9%+32.3%$955.88MN/A-10.48N/AHigh Trading VolumePHARPharming Group2.0343 of 5 stars$13.90+0.1%$30.00+115.8%+92.9%$952.29M$297.20M-106.92280Gap UpHigh Trading VolumeUPBUpstream Bio1.3991 of 5 stars$17.35+3.3%$56.50+225.6%N/A$935.34M$2.37M0.0038SPRYARS Pharmaceuticals2.7701 of 5 stars$9.41-5.5%$32.50+245.4%-29.5%$929.99M$89.15M-19.2090 Related Companies and Tools Related Companies Beam Therapeutics Competitors CRISPR Therapeutics Competitors Intellia Therapeutics Competitors atai Life Sciences Competitors Cronos Group Competitors Trevi Therapeutics Competitors Rapport Therapeutics Competitors Pharming Group Competitors Upstream Bio Competitors ARS Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EDIT) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EDIT Stock Alerts